Core Viewpoint - Shanghai Heyu Biopharmaceutical Technology Co., Ltd. announced that its new oral, highly selective, and effective small molecule CSF-1R inhibitor, Beijiemai® (Pimitidine Hydrochloride Capsules), has received formal acceptance for New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for the systemic treatment of patients with Tenosynovial Giant Cell Tumor (TGCT) [1][2] Group 1 - Beijiemai® is independently developed by the company and has been authorized to Merck for global commercialization [1][3] - The NDA acceptance is based on positive results from the global multicenter, randomized, double-blind, placebo-controlled Phase III MANEUVER study, which showed a significant improvement in objective response rate (ORR) for TGCT patients treated with Beijiemai® compared to the placebo group [2] - Secondary endpoints related to key clinical outcomes for TGCT patients showed significant and clinically meaningful improvements, including enhanced joint range of motion and physical function, as well as reduced stiffness and pain [2] Group 2 - TGCT is a rare locally aggressive tumor occurring in or around joints, leading to swelling, stiffness, and restricted movement, significantly impacting patients' daily activities and quality of life [2] - Beijiemai® has already been approved by the National Medical Products Administration (NMPA) in China for symptomatic TGCT adult patients who may experience functional limitations or severe complications from surgical resection [3] - The drug has also received Breakthrough Therapy Designation (BTD) from the FDA and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for its overseas applications [3]

Core Insights - The drug Beijiemai® (pimitidine hydrochloride capsules) developed by HeYu Pharmaceutical has received formal acceptance of its New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for the systemic treatment of patients with tenosynovial giant cell tumor (TGCT) [4] - Beijiemai® has been approved by the National Medical Products Administration (NMPA) in China for adult patients with symptomatic TGCT who may experience functional limitations or serious complications from surgical resection [2][4] - The NDA acceptance is based on positive results from the global multicenter, randomized, double-blind, placebo-controlled Phase III MANEUVER study, which demonstrated a significant improvement in objective response rate (ORR) for patients treated with Beijiemai® compared to the placebo group [1] Group 1 - TGCT is a rare locally aggressive tumor that occurs in or around joints, leading to swelling, stiffness, and limited mobility, significantly impacting patients' daily activities and quality of life [2] - Beijiemai® is a novel, oral, highly selective, and effective small molecule CSF-1R inhibitor, which is expected to provide an innovative treatment option for TGCT patients globally, addressing unmet clinical needs in this disease area [2] - The drug has also received Breakthrough Therapy Designation (BTD) from the FDA and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) [2]

Core Viewpoint - The new drug application (NDA) for the oral, highly selective, and effective small molecule CSF-1R inhibitor, Beijiemai® (pimitinib hydrochloride capsules), developed by He Yu Pharmaceutical, has been officially accepted by the FDA for the systemic treatment of patients with tenosynovial giant cell tumor (TGCT) [1][2] Group 1: Drug Development and Approval - Beijiemai® has been developed by He Yu Pharmaceutical and is licensed to Merck for global commercialization [1] - The drug received approval from the National Medical Products Administration (NMPA) in China in December 2025 for symptomatic TGCT adult patients who may experience functional limitations or severe complications from surgical resection [1] - The NDA acceptance by the FDA is based on positive results from the global multicenter, randomized, double-blind, placebo-controlled Phase III MANEUVER study [2] Group 2: Clinical Study Results - The study demonstrated that patients with TGCT treated with Beijiemai® showed a significantly higher objective response rate (ORR) at week 25 compared to the placebo group, as assessed by the blinded independent review committee (BIRC) using RECIST v1.1 criteria [2] - All secondary endpoints related to key clinical outcomes for TGCT patients showed significant and clinically meaningful improvements, including enhanced joint range of motion and physical function, as well as reductions in stiffness and pain [2] - Long-term data with a median follow-up of 14.3 months indicated a continuous improvement in ORR for patients who received Beijiemai® treatment from the start of the study [2] Group 3: Disease Context and Market Potential - TGCT is a rare locally aggressive tumor that occurs in or around joints, leading to swelling, stiffness, and restricted movement, significantly impacting patients' daily activities and quality of life [2] - If not treated promptly or if recurrence occurs, TGCT can cause irreversible damage to bones, joints, and surrounding tissues [2] - With the ongoing submissions and future approvals in major global markets, Beijiemai® is expected to provide an innovative treatment option that is effective, well-tolerated, and administered once daily, addressing the unmet clinical needs in this disease area [2]

Core Viewpoint - The new drug application (NDA) for the oral, highly selective, and effective small molecule CSF-1R inhibitor, Beijiemai® (pimitinib hydrochloride capsules), developed by He Yu Pharmaceutical, has been officially accepted by the FDA for the systemic treatment of patients with tenosynovial giant cell tumor (TGCT) [1][2] Group 1: Drug Development and Approval - Beijiemai® was developed independently by He Yu Pharmaceutical and is licensed to Merck for global commercialization [1] - The drug received approval from the National Medical Products Administration (NMPA) in China in December 2025 for symptomatic TGCT adult patients who may experience functional limitations or severe complications from surgical resection [1] - The NDA acceptance by the FDA is based on positive results from the global multicenter, randomized, double-blind, placebo-controlled Phase III MANEUVER study [2] Group 2: Clinical Study Results - The study demonstrated that patients with TGCT treated with Beijiemai® showed a significantly higher objective response rate (ORR) compared to the placebo group at week 25, as assessed by a blinded independent review committee (BIRC) using RECIST v1.1 criteria [2] - All secondary endpoints related to key clinical outcomes for TGCT patients showed significant and clinically meaningful improvements, including enhanced joint range of motion and physical function, as well as reductions in stiffness and pain [2] - Long-term data from a median follow-up of 14.3 months indicated a continuous increase in ORR for patients who received Beijiemai® treatment from the start of the study [2] Group 3: Disease Context and Market Potential - TGCT is a rare locally aggressive tumor that occurs in or around joints, leading to swelling, stiffness, and restricted movement, significantly impacting patients' daily activities and quality of life [2] - If untreated or recurrent, TGCT can cause irreversible damage to bones, joints, and surrounding tissues [2] - With the ongoing submissions and future approvals in major global markets, Beijiemai® is expected to provide an innovative treatment option that is effective, well-tolerated, and administered once daily, addressing the unmet clinical needs in this disease area [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong expectation for future returns exceeding the market benchmark by over 20% within the next 6-12 months [5][10]. Core Insights - The approval of the CSF-1R inhibitor, Beijiemai® (pimitinib), by the NMPA marks a significant milestone as it is the first systemic treatment for tenosynovial giant cell tumor (TGCT) in China and the first independently developed drug in this category [1][5]. - The clinical trial application for the KRAS G12D inhibitor, ABSK141, has also been approved, with an open-label I/II phase study aimed at evaluating its safety and efficacy in patients with advanced solid tumors carrying the KRAS G12D mutation [1]. - Preliminary data from the Phase II clinical study of the oral PD-L1 inhibitor, ABSK043, in combination with the EGFR inhibitor, furmonertinib, for treating non-small cell lung cancer (NSCLC) shows good safety and tolerability [2]. Financial Projections - Revenue forecasts for the company are as follows: 2025 revenue is projected at 612.1 million, 2026 at 678.8 million, and 2027 at 627.2 million, reflecting growth rates of 21.5%, 10.9%, and -7.6% respectively [4][9]. - The net profit attributable to the parent company is expected to reach 82.2 million in 2025, 133.8 million in 2026, and 98.4 million in 2027, with significant growth rates of 190.5% and 62.7% for 2025 and 2026 respectively [4][9]. - The earnings per share (EPS) is projected to be 0.12 in 2025, 0.20 in 2026, and 0.14 in 2027, indicating a positive trend in profitability [4][9].

Core Insights - China is transitioning from a technology provider to an equal partner in the global innovative drug landscape, actively participating in clinical strategy formulation and commercialization in key markets like the U.S. [1] - The recent $2.5 billion clinical trial payment to BaiLi Tianheng signals that high-value business development (BD) transactions in China's innovative drug sector are entering a phase of realization [1] - The record $60.5 billion deal between 3SBio and Pfizer marks a shift of Chinese innovative drugs from fast followers to global pioneers, highlighting the increasing importance of Chinese pharmaceutical companies in the global pharmaceutical landscape [1] - The rapid development of the rare disease drug Beijiemai® by HeYu Pharmaceutical, taking only nine years and seven months from lab to market, exemplifies the "China speed" that is reshaping global drug development efficiency standards [1] Industry Trends - The Chinese innovative drug market is projected to reach 740 billion yuan (approximately $102 billion) by 2025, with expectations to grow to nearly 2.3 trillion yuan by 2030 [2] - The period from 2015 to 2024 is critical for the evolution of the global pharmaceutical innovation landscape and the transformation of China's clinical trial system [4] - The number of innovative drug clinical trials globally has increased by 23.5% over the past decade, with oncology remaining a key research focus, accounting for 32% of trials in 2024 [5] Clinical Development - In the first half of 2025, the China Drug Evaluation Center (CDE) received 6,213 drug registration applications, a 15.83% year-on-year increase, with chemical drugs making up 65.8% of the total [6] - HeYu Pharmaceutical's Beijiemai® received approval from the National Medical Products Administration (NMPA) for treating symptomatic tenosynovial giant cell tumors (TGCT) in adults, based on Phase III trial data showing a 54% objective response rate [1][6] Business Development - By the end of October 2025, Chinese pharmaceutical companies had achieved over $110 billion in external licensing deals, surpassing the total from 2022 to 2024 [8] - The collaboration between Innovent Biologics and Takeda Pharmaceuticals, with a potential total deal value of up to $11.4 billion, exemplifies the shift towards co-development and commercialization models [8] - The trend of biotech companies deepening globalization through various models, including joint development and independent international expansion, is becoming a core engine for growth [9] Globalization Challenges - Chinese innovative drug companies face challenges in international markets, including regulatory diversity, complex drug registration processes, and inconsistent healthcare payment systems [12] - Achieving a unified approach in clinical design and compliance across different regions is crucial for successful internationalization [12] Future Outlook - The Chinese biotech sector is expected to contribute 10% to 15% of new global drug launches in the future, driven by advancements in second-generation technologies and unmet clinical needs [7] - The successful approval of Beijiemai® in China signifies a broader industry shift, indicating that Chinese companies are no longer just serving domestic patients but are aiming to meet global patient needs [14]

Group 1 - The Ministry of Finance and another department issued opinions to implement the State Council's notice on domestic product standards in government procurement, defining that domestic products must be produced within the borders of China [1] - The notice specifies that products produced in special customs supervision areas, such as bonded zones, are considered produced in China, and medical devices with the necessary registration certificates are also included [1] Group 2 - The international gold and silver markets continue to reach new highs, with COMEX gold futures rising by 2.13% to $4480.6 per ounce and silver futures increasing by 2.37% to $69.09 per ounce [2] - Major U.S. stock indices saw gains, with the Dow Jones Industrial Average up 0.47%, the S&P 500 up 0.64%, and the Nasdaq Composite up 0.52%, indicating a positive market trend [2] Group 3 - The National Medical Products Administration released the "Internet Drug and Medical Device Information Service Filing Management Regulations," which will standardize the filing process for internet-based medical services [3] - This regulation aims to guide local authorities in managing the filing process effectively, impacting pharmaceutical e-commerce platforms in Hong Kong [3] Group 4 - Hong Kong's Financial Secretary highlighted the region's significant potential in developing a commodities market, emphasizing its role in serving both national and global needs [4] - The global supply and demand dynamics for various commodities are undergoing profound changes driven by geopolitical factors, technological advancements, and green transitions [4] Group 5 - The Hong Kong Gold Central Clearing System is set to begin trial operations in 2026, with plans for a significant expansion of gold storage capacity at the airport [5] - The government will establish a preparatory group to involve local and international stakeholders in the development of this industry organization [5] Group 6 - NVIDIA's GB300 AI server cabinet is projected to reach a shipment volume of 55,000 units in the next year, driven by major companies like Microsoft and Meta, marking a 129% year-on-year increase [6] - The next-generation Vera Rubin 200 platform is expected to start shipping in Q4 of next year, providing growth momentum for supply chain manufacturers [6] Group 7 - China National Nuclear Corporation announced that its Huizhou Unit 1 is now expected to be operational in the first half of 2026, with both Units 1 and 2 currently in the debugging phase [9] - The operational timeline for these units has been adjusted from previous estimates, reflecting careful consideration of project progress [9] Group 8 - China National Offshore Oil Corporation signed a strategic cooperation agreement with Datang Hainan to develop a green methanol project in Danzhou, with a planned production capacity of 100,000 to 200,000 tons per year [10] - This collaboration aims to explore high-value utilization of biomass and establish a supply chain for green methanol in the region [10] Group 9 - Huayu-B announced that its CSF-1R inhibitor, Beijiemai®, has been approved by China's NMPA for treating symptomatic tenosynovial giant cell tumors in adult patients [11] - The approval will enable Merck to expedite the availability of this product to Chinese patients [11] Group 10 - Sanhua Intelligent Control expects its annual net profit to increase by 25% to 50%, projecting a profit of approximately 3.874 billion to 4.649 billion yuan [12] - The company's net profit, excluding non-recurring gains and losses, is expected to be between 3.679 billion and 4.615 billion yuan, reflecting strong financial performance [12] Group 11 - China Duty Free Group is set to benefit significantly from the recent launch of the Hainan Free Trade Port, with a notable increase in duty-free shopping sales [16] - On the first day of the port's operation, duty-free shopping in Hainan reached 161 million yuan, marking a 61% year-on-year increase [16]

Core Viewpoint - The approval of Beijiemai® (Pimitespib Hydrochloride Capsules) by the NMPA for the treatment of symptomatic tenosynovial giant cell tumors (TGCT) in adult patients marks a significant advancement for the company and provides a new treatment option for patients in China [1] Company Summary - The company's subsidiary, Shanghai Heyu Biopharmaceutical Technology Co., Ltd. ("Heyu Pharma"), announced the approval on December 22, 2025 [1] - Following the approval, Merck will expedite the availability of this product to TGCT patients in China [1]